The effect of subchronic administration of vigabatrin on learning and memory in nonepileptic rats

Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients

Vigabatrin (VGB) has demonstrated high efficacy in infantile spasms (IS) due to tuberous sclerosis. Our first objective was to evaluate the cognitive long term effect outcome of children whose refractory spasms definitely disappeared when VGB was given as an add on drug. Our second objective was to determine the response of generalized epilepsy (infantile spasms) compared to partial epilepsy on cognitive impairment. A non selected series of 13 children underwent psychometric and behavioural evaluation before VGB initiation at a mean of 3 years on VGB treatment. Eight of them could perform detailed neuropsychological tests at follow-up. Seven had infantile spasms (Group I), they all were spasm free before 2 years of age and five remained with rare partial seizures (mean age, 5.5 years). Six others had partial epilepsy without spasms (Group II) and five remained with rare seizures (mean age, 7.5 years). Patients of Group I experienced dramatic changes. Developmental quotient (DQ) significantly rose in six out of seven by ten to more than 45 points (P = 0.03) and autistic behaviour disappeared in five out of the six who presented with. The four tested children had normal verbal level after 5 years and could integrate at school but they remained with marked visuospatial disabilities. By contrast, patients of Group II remained with an unchanged DQ of about 60 so that both groups had similar DQ levels on follow-up. The cessation of spasms with VGB is therefore associated with significant improvement of cognition and behaviour in children with tuberous sclerosis. Controlling secondary generalization induced by infantile spasms seems to be a key factor for mental development.

Studies on the influence of enriched-environment housing combined with systemic administration of an alpha2-adrenergic antagonist on spatial learning and hyperactivity after global ischemia in rats

BACKGROUND AND PURPOSE

The purpose of this study was to determine whether an enriched housing environment and/or systemic administration of the alpha2-adrenergic receptor antagonist atipamezole facilitate the rate of spatial learning after global ischemia in rats.

METHODS

Carotid arteries were closed for 20 minutes after permanent cauterization of vertebral arteries on the previous day. Enriched-environment housing and drug/saline treatment were begun 3 days after ischemia. For rehabilitation, housing in an enriched environment was combined with exploration in a labyrinth. Behavioral tests (the open-arena test and water-maze learning set task) were performed after 1-week periods of drug/saline treatment three times. In addition, the open-arena test was performed to evaluate the baseline level of animals 2 days after the induction of ischemia and at the end of the experiment, when the water-maze task was assessed in another room.

RESULTS

Rats housed in an enriched environment after ischemia showed better acquisition of the water-maze learning set task after 1 week of housing. The influence of atipamezole treatment on this parameter did not reach statistical significance. In the open-arena test, ischemic animals were slightly hyperactive; however, this symptom was eliminated by housing in an enriched environment.

CONCLUSIONS

The present data suggest that housing in an enriched environment facilitates the rate of spatial learning in rats with global ischemia. Rehabilitation also alleviated the hyperactivity observed in ischemic animals.

The systemic administration of tacrine or selegiline facilitate spatial learning in aged fisher 344 rats

When compared to young Fisher 344 rats, aged Fisher 344 rats were impaired in their acquisition of the water maze task as indicated by longer escape latencies and distances to find a hidden platform. In a free swim trial which was performed after the training period, young rats had a better spatial bias, since they spent more time swimming in the previous training quadrant. Tacrine 3 mg/kg, an anticholinesterase, and selegiline 0.25 mg/kg, a MAO-B inhibitor, partially reversed the acquisition deficit in aged rats when administered on their own, and drug-treated aged rats swam more in the previous training quadrant than vehicle-treated aged rats during the free swim trial. Aged rats also swam slower than young rats. Tacrine, but not selegiline, increased swimming speed in aged rats. Taken as a whole, these data support the proposal that tacrine may be effective at alleviating age-related learning impairment and confirm the role of cholinergic dysfunction in the spatial learning deficit in aged rats.

The effects of NMDA receptor antagonists at anticonvulsive doses on the performance of rats in the water maze task

In the present study we investigated the effects of two competitive NMDA receptor antagonists, CGP 37849 (DL-(E)-2-amino-4-methyl-phosphono-3-pentonoic acid) and CGP 39551 (carboxyethyl ester of CGP 37849) as well as MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenz(a,d)cycloheptene-5,10-imine hydrogen maleate), a non-competitive antagonist, administered systemically before training, on the acquisition of a water maze task used to assess spatial learning and memory in rats. The competitive NMDA receptor antagonists dose dependently impaired water maze acquisition (increased escape distance), but did not significantly affect swimming speed in rats. MK-801 induced clear behavioral effects and impaired the acquisition of the water maze task. However, as training advanced drug-treated rats did show a decrease in distance swam per trial before encountering the platform in the water pool. This suggests that drug treatments did not abolish learning. When the anticonvulsive properties of the drugs were determined, MK-801 did not show any protection in the maximal electroshock (MES) test at doses already impairing the acquisition of the water maze task while the two competitive NMDA receptor antagonists protected the rats against seizures at doses not impairing acquisition. This result suggests a wider therapeutic range for CGP 39551 and especially for CGP 37849 than for MK-801 in the treatment of epilepsy.

Effects of single and repeated administration of vigabatrin on the performance of non-epileptic rats in a delayed non-matching to position task

The present experiments were performed to investigate the effects of single and repeated administration of vigabatrin (gamma-vinyl-GABA), a novel antiepileptic drug, on a working memory task (delayed non-matching to position task) in non-epileptic rats. At doses of 100, 300 and 500 mg/kg single administrations of vigabatrin and 50, 100 and 200 mg/kg repeated administrations, vigabatrin did not affect the choice accuracy in the delayed non-matching to position task employing delays of 0, 1, 2, 4, 8 and 16 s, whereas repeated administration with 300 mg/kg and a single dose of 1000 mg/kg decreased the behavioral activity as compared to saline treatment. Previous studies have shown that at doses of 50-200 mg/kg (daily administration) and 200-1000 mg/kg (single administration) vigabatrin has anticonvulsant activity. The present results suggest that vigabatrin does not markedly impair working memory in the low range of antiepileptic/anticonvulsive doses.

Effects of an inhibitor of GABA-aminotransferase (gamma-vinyl-GABA) on the spatial navigation deficit induced by nicotinic blockade

1. The present study investigated whether stimulation of the GABA-ergic system affects spatial navigation (water-maze, WM) deficit induced by nicotinic blockade (mecamylamine). 2. The effects of various doses of gamma-vinyl-GABA (GVG: 50, 150 and 300 mg/kg) and mecamylamine (2.5 and 10 mg/kg) were examined alone and in combination. 3. GVG at the dose 150 mg/kg alone did not impair the performance of rats in the WM task. 4. Mecamylamine at the dose 2.5 and 10 mg/kg clearly impaired the performance of rats in WM task. 5. When the two drugs were co-administered, no interaction between mecamylamine and GVG was observed. 6. Combined nicotinic and muscarinic blockade did not interact as well with GVG administration. 7. Our results do not provide support for any interaction between cholinergic and GABA-ergic mechanisms.

Effects of single and repeated administration of vigabatrin on the performance of rats in a 5-choice serial reaction time task

The present study investigated whether pharmacological stimulation of the GABAergic system can affect attention. The effects of vigabatrin, a novel antiepileptic drug, on the performance of rats in a 5-choice serial reaction time task assessing selective attention were studied. The effects of acute (100, 300, 500 and 1000 mg/kg) and subchronic (50, 100, 200 and 300 mg/kg/day) administration of vigabatrin were investigated. Previous studies have shown that with acute administration of 300-500 mg/kg or subchronic administration of 50-200 mg/kg/day vigabatrin has anticonvulsant activity. At acute doses of 100 and 300 mg/kg or subchronic administration of 50-200 mg/kg/day vigabatrin had no effect on selective attention. At acute dosing of 500 mg/kg, vigabatrin slightly decreased behavioral activity of rats through decreasing the number of trials completed and percent of correct responses. The highest doses used caused an overall behavioral impairment with no marked depletion of any particular function. The results showed that administration of vigabatrin at antiepileptic doses produced no or slight impairment in attentional function. The deficits seen with higher doses were possibly due to a decrease in behavioral activity.

Effects of an inhibitor of GABA-aminotransferase (gamma-vinyl-GABA) on the spatial navigation deficit induced by muscarinic blockade

The present study investigated whether stimulation of the GABAergic system affects spatial navigation [water-maze (WM)] deficit induced by muscarinic blockade (scopolamine). The effects of various doses of gamma-vinyl-GABA (GVG) (50, 150, and 300 mg/kg) and scopolamine (0.4 and 0.1 mg/kg) were examined alone and in combination. GVG at 50 and 150 mg/kg alone did not impair the performance of rats in the WM yask. At 300 mg/kg, GVG caused slight impairment, increasing latency and total distance swim during training trials. Scopolamine at 0.4 mg/kg clearly impaired the performance of rats in the WM task. When the two drugs were coadministered, no interaction between scopolamine and GVG was observed. Our results do not provide support for any interaction between cholinergic muscarinic and GABAergic mechanisms.

Hippocampal mobility-related theta activity is not diminished by vigabatrin, a GABAmimetic antiepileptic drug, in normal rats

Lesions causing loss of hippocampal theta activity have been shown to result in spatial memory deficits in rats. On the other hand, hippocampal theta activity is thought to be associated only with motor activity, and its role in learning/memory is not clear. Vigabatrin, an inhibitor of GABA-tranasminase, causes elevation of brain GABA levels. Previously, we have found that subchronic administration of vigabatrin did not impair spatial learning/memory in a water maze task. This experiment was carried out to further examine the hippocampal effects of vigabatrin by studying whether vigabatrin at antiepileptic doses affects mobility-related hippocampal EEG. Administration of vigabatrin (100 mg/kg or 500 mg/kg, IP) to nonepileptic rats caused no significant changes in mobility-related rhythmic theta activity, and the relative spectral power of theta frequency had a slight increasing tendency. These results suggest that the vigabatrin-induced enhanced GABAergic inhibition does not disturb normal mobility-related hippocampal theta activity.

Gammavinylgaba increases high voltage spindle activity in control and nucleus basalis-lesioned rats after sub-chronic treatment

The present study investigates the effects of gammavinylgaba (GVG, 4 days treatment at 50 and 200 mg/kg), a gabatransaminase inhibitor, on the high-voltage spindle (HVS) activity in control and nucleus basalis-lesioned rats. GVG treatment at 200 mg/kg, but not at 50 mg/kg increased HVS activity in controls. GVG greatly aggravated nucleus basalis magnocellularis (NBM) lesion-induced increase in HVS activity at 200 mg/kg, but not at 50 mg/kg. The present results demonstrate that partial NBM lesions increase the HVS inducing potency of GVG.

Increased GABAergic transmission aggravates nucleus basalis magnocellularis lesion-induced behavioral deficits

Quisqualic acid NBM lesions had no effect on water maze performance, but slightly impaired passive avoidance acquisition. GammavinylGABA treatment alone had no effect on the passive avoidance and water maze performance, but aggravated acquisition deficit in rats subjected to NBM lesioning. However, gammavinylGABA-treated NBM-lesioned rats reached control level of performance.